Literature DB >> 880545

Adenosquamous carcinoma of the endometrium. An entity with an inherent poor prognosis?

O M Salazar, E W DePapp, T A Bonfiglio, M L Feldstein, P Rubin, J H Rudolph.   

Abstract

Mixed adenosquamous carcinoma of the endometrium have been reported in recent years to have a steady increase in incidence, extreme aggressiveness, poor responses to radiation therapy, and a low five-year survival (less than 20%). In the present report, 87 mixed carcinoma (MC) are compared with 260 pure adenocarcinomas (AC) and 29 adenoacanthomas (AA). There were no basic differences in incidence, clinical history, responses to radiation therapy, and prognosis for any of these three entities. Adenocarcinomas of the endometrium with and without squamous elements should be regarded and approached as any pure AC. There is an overall tendency for endometrial carcinomas to be at an early stage at diagnosis and the five-year survival regardless of pathologic type, stage, grade, myometrial invasion, and therapy is 80%.

Entities:  

Mesh:

Year:  1977        PMID: 880545     DOI: 10.1002/1097-0142(197707)40:1<119::aid-cncr2820400121>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Adenoacanthoma of the endometrium: a separate entity or a histological curiosity?

Authors:  H Barrowclough; K W Jaarsma
Journal:  J Clin Pathol       Date:  1980-11       Impact factor: 3.411

2.  Adenoacanthoma of the endometrium: morphological changes induced by human papillomavirus.

Authors:  W F Kealy; P G Annis; J A Barry; J M Hogan
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

3.  Prognostic criteria in patients with endometrial cancer.

Authors:  J Baltzer; K J Lohe; R Kuerzl; K P Scheer; J Zander
Journal:  Arch Gynecol       Date:  1983

4.  Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes.

Authors:  H Tsuda; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1992-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.